Abstract:Objective: To report a case of terbinafine-induced autoimmune hepatitis in a patient with chronic hepatitis B infection. Case summary: A 57-year-old Taiwanese male with chronic hepatitis B virus (HBV) began an oral regimen of terbinafine 250 mg once daily for dermatophyte toenail onychomycosis, despite the manufacturer's recommendation not to use the drug in patients with liver dysfunction. The patient's liver enzyme levels were within normal limits at initiation of therapy. Immediately prior to concluding the 12 week treatment course, he became anorexic with malaise and subsequently developed ascites and jaundice. After a visit to an outside emergency department and positively trending liver function test levels, he was referred to our liver clinic. The patient was taking no other medications or herbal supplements, did not drink alcohol, and did not appear to suffer a flare of HBV infection. The diagnosis was supported by the presence of transient autoantibodies and a liver biopsy consistent with acute autoimmune drug injury. Three weeks after terbinafine was discontinued, peak levels of aspartate aminotransferase (1282 IU/L), alanine aminotransferase (1044 IU/L), and bilirubin (5.9 mg/dL) were noted; his platelet level had decreased to 77 x 10(3)/mm3. He was treated with supportive care that included vitamin K for coagulopathy, diuretics for ascites, and adefovir to prevent hepatitis B exacerbation. The patient's liver function studies began to normalize 6 weeks after terbinafine was discontinued. Discussion: Terbinafine-induced hepatobiliary dysfunction, due to hepatocellular injury, cholestasis, or mixed form, has been reported, but this is the first case of autoimmune hepatitis supported by serologic, biochemical, and biopsy results. Use of the Naranjo probability scale revealed a probable relationship between the patient's hepatitis and terbinafine. Furthermore, the Roussel Uclaf Causality Assessment Method, a scoring system that specifically assesses the likelihood of drug-induced elevated levels of liver-associated enzymes, also supported a probable relationship. The pathogenesis of most drug-induced autoimmune hepatitis remains speculative, likely involving hapten-carrier complex and the cytochrome P450 isoenzymes. In this patient, his chronic HBV carrier state may have predisposed him to this autoimmune reaction. Conclusions: Healthcare practitioners should heed the manufacturer's warning that terbinafine not be used in patients with underlying hepatic disease.

The toxic effects of terbinafine hydrochloride by oral on liver and kidney of feline

[Effects of Ketoconazole on Physiological Function of Liver and Testis in Mice].

Identification of a Reactive Metabolite of Terbinafine: Insights into Terbinafine-Induced Hepatotoxicity

The Safety and Efficacy of Terbinafine in the Treatment of Elderly Patients with Onychomycosis: a Multicenter Trial

Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium

In vitro susceptibility testing of domestic terbinafine hydrochloride against dermatophytes

Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis

Pharmacokinetics of Terbinafine in the Rabbit Ocular Tissues after Topical Administration

Eradicating Otomycosis with Terbinafine Solution: Basic and Clinical Investigation

Meta-analysis on Efficacy and Safety of Terbinafine and Itraconazole in Treatment of Onychomycosis

Clinical presentation of terbinafine‐induced severe liver injury and the value of laboratory monitoring: a Critically Appraised Topic

Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial

Comparison of the Therapeutic Effects of Nano-essence of Artemisia sieberi with the Terbinafine 1% in Animal Model Dermatophytosis

Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection

The Clinical Effect of XTR Combined with Terbinafine in 46 Patients with Toenail Onychomycosis

Study on Efficacy and Safety of Terbinafine Vs. Itraconazole in the Treatment of Tinea Pedis

Toxicologic Effect and Transcriptome Analysis for Short-Term Orally Dosed Enrofloxacin Combined with Two Veterinary Antimicrobials on Rat Liver.

Acute toxicity and subchronic toxicity tests for veterinary concentrated Shuanghuanglian oral liquid

Toxic Effects of Furosine by Oral Intake on Liver and Kidney and Toxicokinetics Research in Mice Acute Toxicity Model

Terbinafine: An update

Fulminant hepatic failure associated with oral administration of diazepam in 11 cats